Developed to combat rural trauma shortages, 'Hemo-Synth' is cleared for emergency use, providing a shelf-stable alternative to donor blood that could save millions of lives in resource-limited settings.
The Central Drugs Standard Control Organisation of India has granted emergency approval to Hemo-Synth, the world's first synthetic blood substitute approved for widespread clinical use. The product, which can be stored at room temperature for up to 24 months, addresses the critical blood shortage crisis that claims an estimated 12,000 lives daily worldwide.
Hemo-Synth was developed by a consortium of Indian and international researchers led by the Indian Institute of Technology Bombay in partnership with Haemonetics Corporation. The synthetic product replicates the oxygen-carrying function of hemoglobin without requiring refrigeration, blood typing, or cross-matching—a game-changer for emergency medicine in resource-limited settings.
"In rural India, patients often die from treatable hemorrhage simply because blood isn't available," said Dr. Anil Kumar, director of the All India Institute of Medical Sciences trauma center. "Hemo-Synth can be stored in any clinic, any ambulance, any health post. It could cut hemorrhage deaths in half within five years."
The product is based on modified bovine hemoglobin encapsulated in synthetic lipid vesicles that mimic red blood cells. The encapsulation prevents the toxic side effects that plagued earlier hemoglobin-based blood substitutes, while the modifications extend the molecule's functional lifespan in circulation.
Clinical trials involving 3,200 trauma patients across 45 Indian hospitals demonstrated that Hemo-Synth maintained adequate tissue oxygenation for up to 12 hours—sufficient time to stabilize patients and transport them to facilities with conventional blood supplies.
"We're not trying to replace blood donation," emphasized Dr. Ravi Mehta, chief scientific officer of the development consortium. "We're creating a bridge—something that keeps patients alive until proper blood products are available. That bridge doesn't exist today, and people are dying for lack of it."
The approval initially covers emergency trauma use, where patients are unconscious or unable to consent and no blood products are available. Planned blood transfusions will continue to use conventional donor blood.
Hemo-Synth has several practical advantages beyond storage stability. It is universal—compatible with all blood types—eliminating the delays associated with typing and matching. It is also pathogen-free, removing the risk of transfusion-transmitted infections that remains a concern in many developing countries.
Manufacturing will begin at a purpose-built facility in Gujarat, with capacity to produce 5 million units annually. The Indian government has committed to subsidizing the product for public hospitals, bringing the per-unit cost to approximately $50—comparable to the cost of collecting and processing conventional blood.
International health organizations have welcomed the approval. The World Health Organization has indicated it will review Hemo-Synth for prequalification, which would facilitate procurement by UN agencies and adoption by other developing countries.
"This represents a paradigm shift in emergency medicine," said Dr. Tedros Adhanom Ghebreyesus, WHO Director-General. "Blood shortage is a silent crisis that affects every country. India's leadership in approving this innovation could save millions of lives globally."
The United States FDA and European Medicines Agency are reviewing similar synthetic blood products, though regulatory timelines in those jurisdictions may extend to 2029. Several African nations have expressed interest in fast-track approval processes similar to India's approach.